Onclive Team

Hyman B Muss, MD, a 2017 Giants of Cancer Care® award winner is a pioneer in the treatment of older patients with cancer.

MDAdvantage Insurance Company, a leading provider of medical professional liability insurance, today announced the 2018 EJI Excellence in Medicine award recipients. Honoring New Jersey healthcare providers, the Excellence in Medicine Awards are among the highest honors presented to New Jersey's medical community.

2017 San Antonio Breast Cancer Symposium Review - February 23

Breakthrough gene therapy for B-cell lymphoma now available at Hackensack University Medical Center.

Chief innovations officer at Hackensack Meridian Health Recognized for Vision, Innovation and Leadership.

Hackensack Meridian Health Hackensack University Medical Center is proud to announce that April Camiling, MSN, RN, AOCNS, BMTCN, oncology nurse specialist in Blood and Marrow Transplant (BMT) at John Theurer Cancer Center - Hackensack University Medical Center, has been recognized by Modern Healthcare as a Rising Star recipient in the 2018 Excellence in Nursing Award program.

Cancer specialists will collaborate on treatment plans and expanding patient access.

People with stage III colon cancer who regularly eat nuts are at significantly lower risk of cancer recurrence and mortality than those who don

Number One Rankings in 10 Key Performance Areas Reinforce McKesson Specialty Health’s Leading Position in the Oncology and Hematology Market

UW Carbone Cancer Center will begin treating adults with a “living drug” that employs their own immune cells to fight a common type of aggressive blood cancer.

Lilly hosted an immersive and interactive reception during the 2018 Gastrointestinal Cancers Symposium entitled,

Oncology drug developers have been able to leverage knowledge about a cause of proliferation— dysregulated activity of the cyclin-dependent kinases (CDKs)—to create a new class of therapy that has rapidly been integrated into the breast cancer treatment paradigm.

McKesson’s total solution streamlines MIPS reporting and provides access to custom quality measures, optimizing MIPS performance for community-based oncology practices

Consultants in Medical Oncology and Hematology (CMOH) has joined The US Oncology Network (The Network).

Results from a recent multicenter, retrospective analysis of 242 patients with advanced non–small cell lung cancer (NSCLC) found that 16% developed hyperprogression during anti–PD-1/PD-L1 treatment.

Providers using iKnowMed certified EHR technology are eligible for Quality Performance bonus points under Merit-based Incentive Payment System.

Patients with myeloproliferative neoplasm‒associated myelofibrosis had prolonged treatment duration and improved survival compared with historical controls when treated with pegylated interferon alfa-2a.

Miami Cancer Institute at Baptist Health will leverage Cota's data, nodal address and analytics to deliver precision medicine and enable the best treatments at the highest quality of care for patients.

Key opinion leaders share the biggest advancements in oncology made this past year.

Two-year findings from the follow-up phase III CONTI-PV randomized trial showed that ropeginterferon alfa-2b, a novel pegylated formulation of interferon alfa-2b, reached a significantly higher rate of complete hematologic response versus hydroxyurea in patients with polycythemia vera.

Progression-free survival remained superior over time in patients with relapsed/refractory multiple myeloma treated treated with combination therapy that included the anti-CD38 antibody daratumumab (Darzalex).

About two-thirds of patients with hydroxyurea-resistant/intolerant polycythemia vera or high-risk essential thrombocytopenia had objective responses to pegylated interferon alfa-2a.

Two-thirds of older patients with acute myeloid leukemia achieved complete responses with the combination of venetoclax (Venclexta) and cytarabine.

Responses to ruxolitinib (Jakafi) in patients with polycythemia vera were maintained by a majority of primary responders at 4 years’ follow-up.

Almost half of patients with relapsed/refractory acute myeloid leukemia achieved complete response with the combination of selinexor (KPT-330) and AraC-containing chemotherapy.

Marcela V. Maus, MD, PhD, evaluates the next generation of chimeric antigen receptor (CAR) T cells in both hematologic malignancies and solid tumors

Adding ibrutinib to a standard frontline chemoimmunotherapy for chronic lymphocytic leukemia induced negative minimum residual disease status in bone marrow for 83% of patients.

The addition of carfilzomib to lenalidomide and dexamethasone for relapsed/refractory multiple myeloma led to a statistically significant 21% reduction in the risk for death compared with lenalidomide and dexamethasone.

City of Hope announced that it has appointed Michael A. Caligiuri, M.D., in a new executive leadership role as president of City of Hope National Medical Center and physician-in-chief.

Patients with cancer who have venous thromboembolism had similar rates of recurrent VTE or bleeding with the oral factor Xa inhibitor edoxaban (Savaysa) or the low-molecular weight heparin dalteparin (Fragmin).